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TRANSLATIONAL RELEVANCE 131 
Brain metastases frequently occur in RET fusion-positive non-small cell lung cancers 132 
(NSCLCs), with an approximate 50% lifetime prevalence reported. Intracranial metastases 133 
are a major cause of morbidity and mortality in this patient population. Thus, there is a need 134 
for novel RET-directed, targeted therapy strategies with high efficacy. Selpercatinib, a 135 
selective and potent RET inhibitor, shows compelling preliminary evidence of activity in 136 
patients with brain metastases. This phase 1/2 trial (LIBRETTO-001) evaluated the efficacy 137 
and safety of selpercatinib in patients with RET fusion-positive NSCLCs with intracranial 138 
metastases. In this study, selpercatinib was well tolerated, achieving high intracranial 139 
response rate, and prolonged intracranial duration of response and intracranial progression-140 
free survival. Combined, these results support selpercatinib as a new standard of care therapy 141 
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Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective 157 
RET inhibitor, approved in the US for RET fusion-positive non-small cell lung cancers 158 
(NSCLCs). 159 
Methods: In the global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RET-160 
altered solid tumors, selpercatinib was dosed orally (160mg twice/day) in 28-day cycles. 161 
Patients with baseline intracranial metastases had MRI/CT scans every 8-weeks for 1 year 162 
(12-weeks thereafter). In this pre-planned analysis of RET fusion-positive NSCLC patients 163 
with baseline intracranial metastases, the primary endpoint was independently-assessed 164 
intracranial objective response rate (ORR) per RECIST 1.1. Secondary endpoints included 165 
intracranial disease control rate, intracranial duration of response, and intracranial 166 
progression-free survival (PFS) independently reviewed. 167 
Results: Eighty NSCLC patients had brain metastases at baseline. Patients were heavily 168 
pretreated (median=2 systemic therapies, range=0–10); 56% of patients received ≥1 course of 169 
intracranial radiation (14% whole brain radiotherapy, 45% stereotactic radiosurgery). Among 170 
22 patients with measurable intracranial disease at baseline, intracranial ORR was 82% 171 
(95%CI=60–95), including 23% with complete responses. Among all intracranial responders 172 
(measurable and non-measurable, n=38), median duration of intracranial response was not 173 
reached (95%CI=9.3–NE) at a median duration of follow-up of 9.5 months (IQR=5.7,12.0). 174 
At 12 months, 55% of intracranial responses were ongoing. In all 80 patients, median 175 
intracranial PFS was 13.7 months (95%CI=10.9-NE) at a median duration of follow-up of 176 
11.0 months (IQR=7.4,16.5). No new safety signals were revealed in patients with brain 177 
metastases compared to the full NSCLC trial population. 178 
Conclusion: Selpercatinib has robust and durable intracranial efficacy in RET fusion-positive 179 
NSCLC patients.   180 
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INTRODUCTION   181 
 182 
The RET (rearranged during transfection) proto-oncogene encodes the RET receptor tyrosine 183 
kinase, a transmembrane glycoprotein that is involved in the development and maintenance 184 
of several tissue types.
1
 Activating RET alterations, such as recurrent gene fusions, lead to 185 
ligand-independent, constitutively active RET tyrosine kinase signaling that drives 186 
oncogenesis and tumor progression.
2-4
 Oncogenic RET fusions are found in 1-2% of non-187 
small cell lung cancers (NSCLCs).
5,6
 A global multi-institutional registry of patients with 188 
RET fusion-positive NSCLC found that approximately half of these patients develop brain 189 
metastases during their lifetime;
7
 leptomeningeal disease has also been observed.
8
  190 
 191 
Intracranial sanctuary site metastasis is a liability shared by many other oncogene-addicted 192 
cancers, including EGFR-mutant or ALK fusion-positive NSCLCs. A major advance in the 193 
management of these tumors has been the development of brain-penetrant tyrosine-kinase 194 
inhibitors.
9,10
 These agents not only prevent or delay intracranial treatment failure, but are 195 
also increasingly utilized as primary therapy for patients with brain metastases instead of 196 
localized interventions such as radiotherapy, an intervention potentially associated with long-197 
term quality of life impairment.
11
  198 
 199 
Selpercatinib (LOXO-292), a highly potent and selective RET inhibitor, has marked and 200 
durable efficacy in patients with treatment-naïve or platinum chemotherapy-treated RET 201 
fusion-positive NSCLCs.
12
 Based on these data, selpercatinib has received approval in the US 202 
for any line of therapy of RET fusion-positive metastatic NSCLCs, and is the first RET-203 
selective inhibitor granted EU approval.
13,14
 Given that several RET fusion-positive cancers 204 
harbor a proclivity for intracranial metastasis, selpercatinib was specifically designed to 205 
achieve levels in the central nervous system (CNS) necessary to inhibit RET. Consistently, 206 
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selpercatinib demonstrated robust intracranial efficacy in orthotopically implanted RET 207 




Preclinical observations, anecdotal case reports 
8,15 
and preliminary experience from a 210 
prospective clinical trial 
7
 suggest that selpercatinib is active in patients with brain 211 
metastases. To date, however, the true intracranial efficacy of selpercatinib in a large 212 
prospective series of RET fusion-positive NSCLCs remains unknown. To address this key 213 
evidence gap, we conducted a pre-planned analysis of selpercatinib in patents with RET 214 
fusion-positive NSCLC and brain metastases enrolled to the global phase 1/2 LIBRETTO-215 
001 trial (NCT03157128). 216 
 217 
METHODS 218 
Study design and treatment 219 
LIBRETTO-001 is an ongoing, global, first-in-human, open label, phase 1/2 clinical trial 220 
(ClinicalTrials.gov NCT03157128) open at 89 investigative sites in 16 countries. A total of 221 
31 sites from 11 countries enrolled at least one patient with a RET fusion-positive NSCLC 222 
and investigator-assessed brain metastases at baseline in the analysis dataset used here. Full 223 
details of the trial design have been published.
12
 Briefly, patients eligible for this pre-planned 224 
analysis were required to meet the following inclusion criteria: age ≥12 years; presence of a 225 
prospectively-identified RET fusion as determined by locally-obtained testing performed in a 226 
certified laboratory; ECOG performance status 0–2; adequate organ function; and a QTc 227 
interval of ≤470 msec. Any number of prior therapies were permitted. Brain imaging was a 228 
requirement at baseline for all RET fusion-positive solid tumor NSCLC patients. Magnetic 229 
resonance imaging (MRI) was preferred; computerized tomography (CT) with contrast was 230 
acceptable if MRI was contraindicated. Patients with known brain metastases were eligible 231 
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for the trial if neurological symptoms and CNS imaging were stable and their steroid dose 232 
was stable for 14 days prior to the first dose of selpercatinib, and no CNS surgery or radiation 233 
had been performed for 28 days (14 days for stereotactic radiosurgery/SRS) prior to dosing. 234 
All prior local treatments for CNS disease (e.g., surgery, whole brain radiation, SRS), the 235 
start and stop dates for each prior local therapy, and the specific lesions treated (if SRS and/or 236 
surgery) were recorded. For patients who had received CNS radiation prior to the trial, 237 
intracranial lesions needed to show post-radiation progression to be selected as a target lesion 238 
at baseline.  239 
 240 
This protocol adhered to the principles of the Declaration of Helsinki and the Good Clinical 241 
Practice Guidelines of the International Conference on Harmonization. The institutional 242 
review board of each investigative site approved the trial, and all patients provided written 243 
informed consent. 244 
 245 
Selpercatinib doses ranged from 20 mg once daily to 240 mg twice daily for patients enrolled 246 
in the phase 1 dose escalation portion of the study. Dose escalation to dose levels determined 247 
to be safe was allowed for phase 1 patients after a minimum of 1 cycle of treatment. In the 248 
phase 2 portion of the study, selpercatinib was dosed orally at 160 mg twice daily (BID) in 249 
28-day continuous cycles. Treatment continued until death, progressive disease, unacceptable 250 
toxicity, or withdrawal of consent. Patients could continue selpercatinib treatment after 251 
documented progression if they were continuing to derive clinical benefit in the opinion of 252 
the investigator. 253 
 254 
The main efficacy endpoint for the current analysis was intracranial objective response rate 255 
(ORR) by RECIST 1.1 
16
 determined by an independent review committee (IRC), a pre-256 
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planned secondary endpoint for the overall LIBRETTO-001 program. The IRC was 257 
composed of expert radiologists who were blinded to investigator-determined systemic 258 
response. IRC radiologists were provided with prior or on-study radiation information and a 259 
history of all prior treatments for CNS disease. Intracranial ORR (%) was defined as the 260 
proportion of patients with a best overall intracranial response of complete response (CR) or 261 
partial response (PR) relative to the total number of patients with baseline intracranial 262 
disease. All responses were required to be confirmed by a repeat assessment performed no 263 
sooner than 28 days later. Intracranial disease control rate (DCR) was defined as the 264 
percentage of patients who had a best overall intracranial response of CR, PR, or stable 265 
disease (SD) lasting 16 weeks or more after selpercatinib initiation. Consistent with RECIST 266 
1.1, patients with exclusively non-measurable intracranial disease at baseline could be 267 
classified for best overall response as CR (in the case where all non-measurable lesions 268 
resolved), progressive disease (PD), or non-CR/non-PD. Another pre-specified secondary 269 
endpoint was intracranial duration of response (DoR) as determined by IRC, defined as the 270 
time from start of an intracranial response until intracranial progression or death, regardless 271 
of cause. Intracranial progression-free survival (PFS) was an exploratory endpoint defined as 272 
the time from treatment start to intracranial disease progression as assessed by IRC or death 273 
from any cause. Extracranial progression was not included in the intracranial PFS assessment. 274 
Safety was another exploratory endpoint for the population with NSCLC and intracranial 275 
metastases.   276 
 277 
Trial Assessments 278 
Radiological tumor assessments (MRI, preferentially; computerized tomography CT, with 279 
and without intravenous contrast when MRI was clinically contraindicated) were conducted 280 
at baseline for all phase 2 RET fusion-positive solid tumor NSCLC patients. Repeat brain 281 
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imaging using the same modality as at baseline was conducted for all patients with brain 282 
metastases identified by baseline imaging every 8 weeks for 1 year, and every 12 weeks 283 
thereafter. Safety was assessed according to the National Cancer Institute Common 284 




Statistical Analysis 287 
All analyses were pre-specified in the Statistical Analysis Plan. The Clopper-Pearson method 288 
was used to construct 95% CIs for response rates. Kaplan-Meier method was used to estimate 289 
median for intracranial DoR and PFS. Median follow up was calculated using the reverse 290 
Kaplan Meier method, i.e. median follow up is calculated like the Kaplan-Meier estimate of 291 
the survival function, but with the meaning of the status indicator reversed so that the event 292 
of interest becomes the censor. SAS statistical software, version 9.2 (SAS Institute, Cary, 293 
NC) was used to perform all analyses. 294 
 295 
Data Sharing 296 
Eli Lilly and Company provides access to all individual participant data collected during the 297 
trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are 298 
available to request 6 months after the indication studied has been approved in the USA and 299 
EU and after primary publication acceptance, whichever is later. No expiration date of data 300 
requests is currently set once they are made available. Access is provided after a proposal has 301 
been approved by an independent review committee identified for this purpose and after 302 
receipt of a signed data sharing agreement. Data and documents, including the study protocol, 303 
statistical analysis plan, clinical study report, and blank or annotated case report forms will be 304 
provided in a secure data sharing environment for up to 2 years per proposal. For details on 305 
submitting a request, see the Vivli website: www.vivli.org. 306 
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RESULTS  307 
Baseline patient characteristics and treatment 308 
A total of 531 patients with RET fusion-positive cancers were enrolled to phase 1 or phase 2 309 
of the trial between May 2017 and June 17, 2019, including 80 patients with RET fusion-310 
positive NSCLC and investigator-determined baseline brain metastases (92.5% by MRI, 5% 311 
by CT, 2.5% missing) that met criteria for inclusion in the current analysis (online appendix, 312 
Figure S1). Among these 80 patients, 22 patients had at least one baseline measurable 313 
intracranial lesion and 58 had exclusively non-measurable baseline intracranial lesions. 314 
 315 
The demographic and disease characteristics of patients with baseline brain metastases are 316 
summarized in Table 1. The median age was 62 years (range 36–86 years), and most patients 317 
had an ECOG performance status of zero or one. Consistent with previous analyses, the most 318 
common RET fusion partner was KIF5B (70% of patients). Most patients had received prior 319 
systemic therapy (91%), with a median of two prior treatments (range 0–10), including 79% 320 
of patients who were treated with platinum-based chemotherapy and 41% of patients who 321 
were treated with one or more multi-kinase inhibitors. Prior therapy for brain metastases 322 
included surgery in 9%, stereotactic radiosurgery in 45%, and whole brain radiotherapy 323 
(WBRT) in 14% of patients. Of the 45 patients who received prior cranial radiotherapy, 73% 324 
had completed this therapy at least 2 months prior to beginning selpercatinib treatment. 325 
 326 
At the time of data cut-off, 46 of the 80 NSCLC patients with brain metastases (58%) 327 
remained on therapy with selpercatinib; 23 of the 80 patients (29%) had discontinued 328 
treatment due to progressive disease (any progressive disease, not limited to intracranial 329 
metastases progression) (online appendix, Table S1). After accounting for intra-patient dose 330 
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escalation permitted during the phase 1 portion of the trial, 95% of patients received at least 331 
one dose of selpercatinib at the recommended phase 2 dose of 160 mg twice daily.  332 
 333 
Selpercatinib intracranial efficacy  334 
At the time of the data cutoff, the median duration of follow-up was 9.5 months (interquartile 335 
range, IQR 5.7, 12.0 months). Among the 22 patients with measurable intracranial disease at 336 
baseline, the intracranial ORR was 82% (95% CI = 60–95), including 23% with a complete 337 
response and 59% with a partial response (Table 2, Figure 1). In addition, 18% of patients 338 
exhibited stable disease as the best response to selpercatinib. Because all the patients 339 
achieved a tumor response or disease stabilization, the intracranial disease control rate was 340 
100%. Among the subset of eight patients with measurable disease and prior cranial 341 
radiotherapy, the intracranial ORR was 75% (six of eight patients responding, 95% CI = 35–342 
97) (online appendix, Table S2). The intracranial ORR for patients without prior cranial 343 
radiotherapy was 86% (12 of 14 patients responding, 95% CI = 57–98).  344 
 345 
Among the remaining 58 patients with exclusively non-measurable intracranial disease at 346 
baseline, 34% (20 of 58 patients) achieved a complete intracranial response on the basis of 347 
complete resolution of all non-measurable lesions and 29 patients had non-CR/non-PD (CR 348 
and non-CR/non-PD corresponds to the clinical benefit rate for non-measurable intracranial 349 
disease). Only five patients (9%) had progressive disease as best intracranial response (online 350 
appendix, Table S3).  351 
 352 
Thirty-eight patients from the 80-patient population (48%) with baseline brain metastases had 353 
an intracranial response to selpercatinib. Among this group of responders, the median 354 
intracranial DoR was not reached (95% CI = 9.3, NE) (Table 3, Figure 2A) at a median 355 
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duration of follow-up of 9.5 months (IQR 5.7,12.0). Overall, 71% were censored at the time 356 
of the analysis. At 1-year, 55% (95% CI = 32–73) of intracranial responses were ongoing. Of 357 
note, the longest intracranial response was ongoing at 21.2 months. Among all 80 patients, 358 
the median intracranial PFS was 13.7 months (Table 3, Figure 2B), although this median 359 
estimate is unstable as only 30 patients (38%) had experienced an event at a median duration 360 
of follow-up of 11.0 months (IQR 7.4,16.5). Time to response and response duration are 361 
displayed in Figure 3 for all responders (n=38).   362 
 363 
Selpercatinib safety 364 
Among patients with NSCLC and baseline brain metastases, selpercatinib treatment was 365 
associated with a low rate of treatment discontinuation due to adverse events judged by the 366 
investigator as possibly related to selpercatinib treatment (TRAEs) (3%, two of 80 patients). 367 
Table S4 summarizes total (all grade) treatment-emergent adverse events (TEAEs) and 368 
TRAEs. TEAEs and TRAEs were reported at similar levels in patients with baseline 369 
intracranial disease as in all RET fusion-positive NSCLCs with and without intracranial 370 
disease (n=253).  371 
 372 
Among patients with intracranial disease, most TEAEs and TRAEs were low grade (Table 373 
S5). The only TEAEs reported as grade 3/4 in >10% of patients with NSCLC and baseline 374 
brain metastases were alanine aminotransferase (ALT) increase (18%), aspartate 375 
aminotransferase (AST) increase (11%), hypertension (21%, all grade 3), and hyponatraemia 376 
(11%). Grade 3/4 elevated ALT and AST and hypertension were reported at similar levels as 377 
TRAEs. No Grade 5 TRAEs were reported among the patients with NSCLC and baseline 378 
brain metastases.  379 
 380 
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Intracranial metastases are a major cause of morbidity and mortality for patients with 382 
oncogene-addicted cancers. The results of this global, multicenter study demonstrate that 383 
selpercatinib has robust intracranial efficacy by blinded independent review of patients with 384 
RET fusion-positive NSCLCs and brain metastases. The drug achieved a high intracranial 385 
response rate and the intracranial duration of response and intracranial progression-free 386 
survival were prolonged. Moreover, selpercatinib treatment was well tolerated in this patient 387 
population, with no new safety signals identified. Taken together, these data support 388 
selpercatinib as a new standard of care for primary treatment of brain metastases for patients 389 
with RET fusion-positive NSCLC. Comprehensive molecular profiling analysis is warranted 390 
in the future to further analyze the biomarkers of intracranial response and resistance to 391 
selpercatinib. 392 
 393 
The intracranial activity of selpercatinib in this phase 1/2 trial is broadly consistent with the 394 
intracranial activity observed with other contemporary targeted therapies for genomically-395 
driven NSCLCs. In ALK fusion-positive lung cancers, alectinib achieved an intracranial ORR 396 
of 64%, an intracranial disease control rate of 90%, and durable disease control (median 397 
intracranial duration of response of 10.8 months) among patients with measurable disease in a 398 
comparable analysis of two single arm phase 2 trials.
10
 At 6 months, 58% of patients were 399 
progression/death-free. In EGFR-mutant lung cancers, osimertinib achieved an intracranial 400 
ORR of 54% and an intracranial disease control rate of 92% in a pooled analysis of two phase 401 
2 trials. 
18
 At 6 months, 72% of patients were intracranial progression/death-free. By 402 
comparison, selpercatinib treatment resulted in an intracranial ORR of 82% and an 403 
intracranial disease control rate of 100%, and at 6 months, 79% of patients were intracranial 404 
progression/death-free. Median intracranial duration of response was not reached (95% CI = 405 
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9.3, NE).  Both alectinib and osimertinib are recognized as standards of care for tyrosine 406 
kinase inhibitor-naïve patients with ALK fusion-positive and EGFR-mutant lung cancers, 407 
respectively, similar to the role of selpercatinib in RET fusion-positive lung cancers.  408 
 409 
Selpercatinib’s activity in the CNS has important implications beyond RET fusion-positive 410 
NSCLCs with brain metastases. A complete response to selpercatinib in leptomeningeal 411 
disease has already been described in a patient with RET fusion-positive NSCLC,
8
 412 
demonstrating the activity of the drug beyond parenchymal disease. Selpercatinib has been 413 
shown to be active against intracranial metastases in a patient with RET fusion-positive 414 
thyroid cancer,
19
 a patient with RET-mutant medullary thyroid cancer,
20
 and a pediatric 415 
patient with RET fusion-positive congenital mesoblastic nephroma.
21
 LIBRETTO-001 416 
continues to enroll patients with non-lung/non-thyroid cancers that harbor RET fusions or 417 
mutations. Additional confirmation of the drug’s activity in this setting will help establish the 418 
overall impact of selpercatinib on intracranial disease in patients with RET-dependent 419 
cancers of any histology in both adult and pediatric populations. 420 
 421 
While this prospective, pre-planned, independently-reviewed analysis has many strengths, it 422 
does have some important limitations. Patients in this cohort had received a variety of both 423 
systemic and local therapies for management of their RET fusion-positive NSCLCs. Despite 424 
this, intracranial activity was observed across various treatment subgroups. In addition, at the 425 
time of analysis, a majority of patients remained progression-free and a majority of responses 426 
were ongoing; thus, stable medians could not be estimated. Ongoing follow-up will reveal 427 
more precise estimates of intracranial response durability and progression-free survival. 428 
Moreover, this study did not specifically address whether selpercatinib can prevent or delay 429 
intracranial progression in patients with NSCLC that begin treatment without intracranial 430 
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involvement. As a phase 1/2 trial, LIBRETTO-001 did not require head and neck MRI/CT 431 
scans during treatment unless intracranial disease was identified at baseline and the trial 432 
could not address this question. Intriguingly, other tyrosine kinase inhibitors with substantial 433 
intracranial activity have already been shown to prolong the time to the acquisition of central 434 
nervous system metastases in fusion-positive lung cancers compared to earlier-generation 435 
kinase inhibitors with less optimal intracranial activity.
22,23
 However, there is a lack of 436 
prospective data evaluating long-term outcomes of tyrosine kinase inhibitors alone compared 437 
to SRS and tyrosine kinase inhibitors in managing brain metastases. 438 
 439 
Selpercatinib is currently being evaluated in LIBRETTO-431 (NCT04194944), an ongoing 440 
randomized, global, phase 3 study of selpercatinib versus platinum-pemetrexed with or 441 
without pembrolizumab in treatment-naïve patients with RET fusion-positive NSCLCs. This 442 
trial will allow the further characterization of selpercatinib activity in patients with NSCLC 443 
and intracranial metastases.  444 
 445 
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Table 1. Demographic and disease characteristics of patients with RET fusion-positive 533 
NSCLC and intracranial disease 534 
Characteristics 
All patients with RET fusion-positive NSCLC 
and intracranial metastases (N=80) 
Age 
 
     Median (range), years 62 (36–86) 
Sex, n (%)  
     Female 54 (68) 
     Male 26 (33) 
Race, n (%)  
     White 44 (55) 
     Asian 31 (39) 
     Black or African American 2 (3) 
     Other 2 (3) 
     Unknown 1 (1) 
Smoking history, n (%)  
     Never 63 (79) 
     Former 16 (20) 
     Current 1 (1) 
ECOG performance status, n (%)  
     0 22 (28) 
     1 54 (68) 
     2 4 (5) 
NSCLC histological subtype, n (%)  
     Adenocarcinoma 69 (86) 
     Large cell neuroendocrine carcinoma 2 (3) 
     NSCLC-NOS 8 (10) 
     Other 1 (1) 
RET fusion partner, n (%)  
     KIF5B 56 (70) 
     CCDC6 11 (14) 
     NCOA4 2 (3) 
     Other 4 (5) 
     Unknown a 7 (9) 
Prior therapy, n (%)  
     Number of prior systemic regimens  
          0 7 (9) 
          1–2 43 (54) 
          3 or more 30 (38) 
     Median prior systemic regimen (range) 2 (0–10) 
     Type of prior systemic therapy b  
          Platinum chemotherapy 63 (79) 
          Anti PD-1/PD-L1 antibody 43 (54) 
          Multi-kinase inhibitor 33 (41) 
          Taxane chemotherapy 25 (31) 
          Other systemic therapy 31 (39) 
     Intracranial radiotherapy b  45 (56) 
          Whole brain radiation therapy 11 (14) 
          Stereotactic radiosurgery 36 (45) 
     Intracranial radiotherapy timing  
          Completed >2 months prior to selpercatinib treatment 33 (41) 
     Intracranial surgery 7 (9) 
a RET fusion identified by molecular analysis with an assay unable to identify the fusion partner (e.g. fluorescence in situ hybridization). 535 
b Patients may be counted in more than one row. 536 
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Table 2. Intracranial tumor response by independent review committee assessment in 537 
patients with RET fusion-positive NSCLC and measurable intracranial disease per 538 
RECIST 1.1.  539 
 
Patients with measurable  
intracranial disease (N=22) 
Intracranial objective response rate, n (%) 18 (82) 
     95% confidence interval a 60 – 95 
Intracranial best overall response, n (%)  
     Complete response  5 (23) 
     Partial response 13 (59) 
     Stable disease 4 (18) 
     Progressive disease 0 
Intracranial disease control rate, n (%) b 22 (100) 
a 95% confidence interval was calculated using Clopper-Pearson method. 540 
b Intracranial disease control rate was defined as the percentage of patients who had a best overall intracranial response of complete 541 
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Table 3. Duration of intracranial tumor response and intracranial progression-free 547 
survival by independent review committee assessment in patients with RET fusion-548 
positive NSCLC and measurable and non-measurable intracranial disease 549 
 Total patients (N=80) 
Duration of intracranial response  
     Responders a 38 
     Censored, n (%) b 27 (71) 
     Intracranial duration of response, median (months) (95% CI) c,d NE (9.3–NE) 
     Intracranial duration of follow-up, median (months) (IQR) c 9.5 (5.7, 12.0) 
     Intracranial duration of response c,e  
         % of patients ≥6 months (95% CI) 91 (75– 97) 
         % of patients ≥12 months (95% CI) 55 (32–73) 
Progression-free survival  
     Censored, n (%) b 50 (62.5) 
     Median, months (95% CI) c,d 13.7 (10.9–NE) 
     Median follow-up, (months) (IQR) c 11.0 (7.4, 16.5) 
     % progression/death-free c,e  
         ≥6 months (95% CI) 79 (68–87) 
         ≥12 months (95% CI) 55 (41–67) 
Abbreviations: CI, confidence interval; IQR, interquartile range;  NE, not estimable 550 
a Patients with intracranial best response of CR or PR based on independent review committee assessments using RECIST (version 1.1). 551 
b Status as of the patient’s last disease assessment on or before 16 Dec 2019. 552 
c Estimate based on Kaplan-Meier method. 553 
d 95% confidence interval was calculated using Brookmeyer and Crowley method. 554 
e 95% confidence interval was calculated using Greenwood’s formula. 555 
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Figure Legend  
Figure 1. Intracranial response to selpercatinib. A waterfall plot of the maximum change in 
intracranial tumor size is shown for the 22 patients with measurable disease at baseline. Vertical 
bars represent the best percent change from baseline in the sum of diameters for all intracranial 
target lesions, with the color of the bar representing the corresponding tumor response 
designation. Symbols represent prior stereotactic radiosurgery (SRS) and prior systemic 
therapies. Note: because the intracranial best overall response in Table 2 is based on RECIST 1.1 
requirements, including the need for a confirmatory scan, the tumor response designation does 
not exactly correlate with table data.  
Abbreviations: MKI, multi-kinase inhibitor 
 
Figure 2. Kaplan-Meier plot of (A) intracranial duration of response and (B) intracranial 
progression-free survival. (A) The plot depicts the duration of response for all responding 
patients with measurable or non-measurable intracranial metastases. (B) The plot was 
constructed with data derived from all patients with measurable or non-measurable intracranial 
metastases treated with selpercatinib.   
Abbreviations: DoR, duration of response; NE, non-estimable; PFS, progression-free survival 
 
 
Figure 3. Duration of selpercatinib therapy.  
Treatment duration, time to intracranial response, and intracranial progression events are shown 
in this swimmer’s plot for patients with measurable and non-measurable intracranial disease 
(n=38). The complete and partial response symbols indicate the time of the first scan showing an 
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